ACRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aclaris Therapeutics Inc (ACRS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company has weak financial performance, no significant positive trading signals, and mixed technical indicators. While there is a positive analyst rating and a potential catalyst in the ATI-052 trial, the poor financial results and lack of recent insider or hedge fund activity make it prudent to hold off on investing right now.
The MACD is negative and contracting, RSI is neutral at 46.502, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 3.111, with resistance at 3.372 and support at 2.849. Overall, the technical indicators suggest a neutral trend.
Craig-Hallum initiated coverage with a Buy rating and a $10 price target, citing potential in the ATI-052 trial and valuation upside. Positive interim results from the ATI-052 Phase 1a trial were reported.
The company missed Q4 EPS and revenue expectations, with revenue dropping 85.9% YoY and net income declining 79.5% YoY. Cash reserves have also decreased significantly. There is no recent insider, hedge fund, or congress trading activity, and the stock lacks significant trading momentum.
In Q4 2025, revenue dropped to $1.3 million (-85.94% YoY), net income fell to -$19.8 million (-79.50% YoY), and EPS decreased to -$0.16 (-84.16% YoY). Gross margin improved to -13.44%, but overall financial performance remains weak.
Craig-Hallum initiated coverage with a Buy rating and a $10 price target, citing proof-of-concept potential and valuation upside ahead of Phase 1b data for ATI-052.
